
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc. demonstrated a robust recovery in its third-quarter 2025 results, with total revenues reaching $4.22 million, marking a significant 105% increase quarter-over-quarter from $2.06 million in the previous quarter. Additionally, the company reported an improvement in gross margins, rising to 60.3% compared to 39.8% in the second quarter of 2025. The positive sales recovery signals resilience against prior challenges, indicating potential for continued growth, especially in light of the recent non-binding merger agreement with Applied Digital Cloud.
Bears say
The financial analyst notes that Ekso Bionics Holdings experienced a revenue miss in the previous quarter, attributed to order delays in enterprise sales totaling $1.5 million. In the third quarter of 2025, the company reported revenues of $4.23 million and a net loss of $0.54 per share, which, while better than consensus estimates, still indicates ongoing financial challenges. Consequently, the downgrading to a Neutral rating reflects concerns over consistent revenue growth and profitability within the company's operational segments.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares